Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 10/20 | 0.45 |
| ▸ | TP53 | P04637 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | PTDSS1 | P48651 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17366167 | 0.74 | MDM2 (0.48) | MDM2TP53MAPTRXFP1MEN1 | |
| SCHEMBL17366153 | 0.72 | MDM2 (0.52) | MDM2TP53MEN1KMT2A | |
| SCHEMBL30121977 | 0.72 | MDM2 (0.64) | MDM2TP53MAPTMEN1KMT2A | |
| SCHEMBL17366161 | 0.71 | MDM2 (0.51) | MDM2TP53MAPTMEN1KMT2A | |
| SCHEMBL17366177 | 0.71 | MEN1 (0.48) | MDM2TP53MAPTHCRTR1HCRTR2 | |
| SCHEMBL17366174 | 0.69 | MDM2 (0.58) | MDM2TP53MAPTMEN1KMT2A | |
| SCHEMBL29872427 | 0.69 | MDM2 (0.39) | MDM2 | |
| SCHEMBL17366156 | 0.68 | MDM2 (0.60) | MDM2TP53MAPTMEN1KMT2A | |
| SCHEMBL17366151 | 0.67 | MDM2 (0.58) | MDM2TP53MAPTMEN1KMT2A | |
| SCHEMBL17366169 | 0.67 | MDM2 (0.58) | MDM2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | MDM2 2/4885TP53 1/4885MAPT 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.